You are here:

atazanavir & cobicistat (Evotaz)

Advice

following an abbreviated submission

atazanavir/cobicistat (Evotaz®) is accepted for use within NHS Scotland.

Indication under review: in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.

Pharmacokinetic studies have demonstrated that atazanavir plus cobicistat is bioequivalent (in terms of atazanavir exposure) to ritonavir-boosted atazanavir.

For patients in whom atazanavir is an appropriate treatment, atazanavir/cobicistat (Evotaz®) provides a combination product at a small cost premium compared to ritonavir-boosted atazanavir.

Drug Details

Drug Name: atazanavir & cobicistat (Evotaz)
SMC Drug ID: 1098/15
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: In combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 9 November 2015

Back